CHU Saint Pierre

The pulmonology department at CHU Saint Pierre is investigating new therapeutic options for lung infections caused by atypical bacteria.

• Adult patients with newly diagnosed nontuberculous mycobacterial lung infection
• Evaluation of inhaled antibiotic formulations for Mycobacterium avium complex
• Studies on antimicrobial resistance patterns in respiratory isolates

Trials focus on improving treatment efficacy, reducing side‑effects, and enhancing quality of life for those with chronic bacterial lung disease.

Research at the site includes investigations into heart‑related complications that intersect with respiratory health.

• High cardiovascular risk patients with coexisting COPD
• Post‑cardiac arrest syndrome and neuro‑protective strategies
• Hypertension management in individuals with chronic lung disease

The aim is to evaluate safety and effectiveness of interventions that address both cardiac and pulmonary outcomes.

Studies are exploring rare genetic conditions that affect the respiratory system from birth.

• Genetic forms of severe early‑onset asthma
• Inherited surfactant protein deficiencies leading to respiratory failure
• Neonatal bronchopulmonary dysplasia and long‑term lung function

Objectives include characterising disease mechanisms and testing targeted therapies to improve survival and lung growth.

The centre links gastrointestinal inflammation with pulmonary manifestations.

• Moderate to severe Crohn’s disease with extra‑intestinal lung involvement
• Ulcerative colitis patients experiencing pulmonary complications
• Impact of biologic therapy on gut‑lung axis inflammation

Research aims to clarify how treating intestinal inflammation can reduce respiratory symptoms and improve overall health.

Clinical work includes trials that assess the safety of respiratory treatments during pregnancy.

• Pharmacokinetics of antiretroviral agents in pregnant women living with HIV
• Effects of inhaled therapies on maternal and fetal outcomes
• Vaccine responses in HIV‑positive pregnant women

The goal is to ensure effective disease control while safeguarding maternal and neonatal health.

Investigations address blood‑related disorders that intersect with lung pathology.

• Sickle cell disease and its impact on pulmonary function
• Evaluation of novel agents to reduce vaso‑occlusive crises in the lungs
• Immune‑modulating therapies for hematologic malignancies with lung involvement

Studies seek to improve respiratory outcomes and overall disease management for affected patients.

The department conducts trials on autoimmune conditions that frequently affect the lungs.

• Primary Sjögren’s syndrome with pulmonary manifestations
• Severe allergic and eosinophilic asthma treated with biologics
• Psoriatic arthritis and its impact on respiratory health

Objectives include assessing efficacy of targeted immunotherapies and monitoring long‑term safety.

Research explores how musculoskeletal disorders influence breathing mechanics.

• Rheumatoid arthritis patients with interstitial lung disease
• Impact of systemic inflammation on pulmonary function in arthritis
• Evaluation of anti‑TNF strategies on both joint and lung outcomes

The studies aim to identify therapeutic approaches that address both joint and respiratory health.

Oncology trials at the site focus on cancers that involve the thoracic cavity or require lung‑related care.

• Non‑small cell lung cancer after prior immunotherapy
• Platinum‑resistant ovarian cancer with investigational maintenance therapy
• Early‑stage hormone‑receptor positive breast cancer assessing adjuvant endocrine combinations

Efforts are directed at improving survival, reducing recurrence, and evaluating tolerability of new drug combinations.

Trials investigate neurological conditions that have secondary respiratory effects.

• Post‑anoxic brain injury and strategies to protect lung function
• Coma management protocols incorporating pulmonary support
• Neuro‑protective interventions after cardiac arrest

The purpose is to enhance neurological recovery while minimizing pulmonary complications.

The core focus of the pulmonology unit is advancing care for chronic and infectious lung disorders.

• Chronic obstructive pulmonary disease (COPD) with exacerbation prevention studies
• Non‑cystic fibrosis bronchiectasis and novel inhaled therapies
• Nontuberculous mycobacterial lung infection treatment trials

Research aims to test new inhaled antibiotics, evaluate anti‑inflammatory agents, and improve long‑term disease control.

Studies address dermatologic conditions with systemic involvement that may affect breathing.

• Moderate‑to‑severe psoriasis and its impact on pulmonary inflammation
• Psoriatic arthritis trials including respiratory safety endpoints
• Assessment of biologic therapy on skin and lung symptom overlap

The goal is to determine whether skin‑targeted treatments also confer respiratory benefits.

Viral infection research includes both respiratory viruses and systemic viral diseases.

• HIV‑positive patients receiving antiretroviral therapy and lung health monitoring
• Measles vaccine response studies in adult volunteers
• Evaluation of HSV‑2 therapeutic vaccine safety and efficacy

Objectives focus on enhancing antiviral strategies while protecting respiratory function.

Investigations probe immune mechanisms that underlie respiratory disease progression.

• Immune system phenotyping in severe asthma patients
• Biomarker discovery for predicting response to biologic agents
• Study of systemic inflammation markers after cardiac surgery

The aim is to translate immunological insights into personalized lung‑targeted therapies.

The site explores fundamental immune pathways that influence pulmonary disease.

• Evaluation of T‑cell modulation in COPD exacerbation prevention
• Impact of cytokine blockade on eosinophilic asthma outcomes
• Assessment of innate immunity alterations in nontuberculous mycobacterial infection

Research seeks to identify actionable targets for next‑generation immunotherapies.

Additional exploratory studies address cross‑disciplinary questions that do not fit a single therapeutic category.

• Proactive therapeutic drug monitoring versus standard care in psoriasis
• Effect of hypertonic sodium lactate infusion on brain injury after cardiac arrest
• Doxycycline post‑exposure prophylaxis for bacterial STIs among HIV‑positive individuals

These projects aim to refine clinical practices, improve patient safety, and generate novel evidence for future guidelines.